At the time of writing, Rhythm Pharmaceuticals Inc [RYTM] stock is trading at $60.23, up 4.33%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RYTM shares have gain 15.92% over the last week, with a monthly amount glided 20.32%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] stock has seen the most recent analyst activity on April 07, 2025, when BofA Securities upgraded its rating to a Buy but kept the price target unchanged to $63 for it. On January 02, 2025, Jefferies initiated with a Buy rating and assigned a price target of $80 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $76 on December 20, 2024. Guggenheim initiated its recommendation with a Buy and recommended $70 as its price target on October 21, 2024. H.C. Wainwright started tracking with a Buy rating for this stock on September 18, 2024, and assigned it a price target of $64. In a note dated September 17, 2024, JMP Securities initiated an Mkt Outperform rating and provided a target price of $64 on this stock.
For the past year, the stock price of Rhythm Pharmaceuticals Inc fluctuated between $35.17 and $68.58. Currently, Wall Street analysts expect the stock to reach $71.6 within the next 12 months. Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] shares were valued at $60.23 at the most recent close of the market. An investor can expect a potential return of 18.88% based on the average RYTM price forecast.
Analyzing the RYTM fundamentals
According to Rhythm Pharmaceuticals Inc [NASDAQ:RYTM], the company’s sales were 130.13M for trailing twelve months, which represents an 72.61% jump. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -2.04%, Pretax Profit Margin comes in at -2.0%, and Net Profit Margin reading is -2.01%. To continue investigating profitability, this company’s Return on Assets is posted at -0.67, Equity is -3.79 and Total Capital is -0.96. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 52.91 points at the first support level, and at 45.60 for the second support level. However, for the 1st resistance point, the stock is sitting at 64.49, and for the 2nd resistance point, it is at 68.76.
Ratios To Look Out For
It is important to note that Rhythm Pharmaceuticals Inc [NASDAQ:RYTM] has a current ratio of 3.24. In addition, the Quick Ratio stands at 3.08 and the Cash Ratio stands at 0.77. Considering the valuation of this stock, the price to sales ratio is 29.26, the price to book ratio is 172.94.
Transactions by insiders
Recent insider trading involved PAMELA CRAMER, Officer, that happened on Apr 08 ’25 when 20760.0 shares were purchased. Officer, YANN MAZZABRAUD completed a deal on Apr 08 ’25 to buy 17750.0 shares. Meanwhile, Corporate Controller & CAO German Christopher Paul sold 344.0 shares on Mar 21 ’25.
